Mitral Valve Prolapse: Symptoms, Risks, Surgery, and Treatment

What is Mitral Valve Prolapse?

Mitral valve prolapse (MVP) is a common cardiac condition in which one or both leaflets (cusps) of the mitral valve, one of the four valves within the heart, bulge backward into the left atrium when the heart contracts. This abnormal movement can impair the valve’s ability to close properly and, in some cases, allows blood to flow in the wrong direction. This is known as mitral regurgitation (or mitral insufficiency).

The Wide Spectrum of MVP

The clinical significance of MVP varies enormously from patient to patient:

• The majority of individuals with MVP have no symptoms and no significant regurgitation. For them, the condition is essentially a benign anatomical variant that requires only periodic monitoring.

• A minority develop significant mitral regurgitation, which can cause:

  • Palpitations: a sensation of the heart skipping beats, pounding, or racing
  • Shortness of breath (dyspnea)
  • Chest pain or discomfort
  • Progressive cardiac enlargement and elevated pressure in the left atrium and pulmonary circulation

When severe, regurgitation can lead to important complications including:

• Arrhythmias are abnormal heart rhythms
• Infective endocarditis: infection of the heart valves and inner lining

How Common Is MVP?

Historically, MVP was believed to affect 5–15% of the population. However, as echocardiography became the diagnostic standard and replaced less precise auscultatory criteria, many previously diagnosed patients were found to have normal valves. Current evidence suggests that fewer than 3% of the population have true MVP, and an even smaller proportion develop serious complications.

When treatment is needed, it ranges from simple lifestyle modifications and medication for symptom control to surgical intervention. When surgery is required, valve repair is the strongly preferred approach over replacement, as it:

• Better preserves long-term cardiac function
• Improves survival and reduces the risk of endocarditis
• Typically does not require lifelong anticoagulation therapy

---

Anatomy of the Mitral Valve

How the Mitral Valve Works Normally

The mitral valve is a bicuspid (two-leaflet) valve positioned between the left atrium (upper chamber) and the left ventricle (lower chamber). Its fundamental function is to act as a one-way gate: allowing blood to flow from the left atrium into the left ventricle during cardiac relaxation (diastole), while preventing any backflow from the ventricle into the atrium during cardiac contraction (systole).

The right side of the heart has an analogous valve, the tricuspid valve, separating the right atrium from the right ventricle.

The cardiac cycle proceeds as follows:

1. Diastole: The atria contract and push blood into the relaxed ventricles. The mitral and tricuspid valves open to allow blood through.
2. Systole: The ventricles contract to eject blood out of the heart. The mitral and tricuspid valves snap shut, forming a tight seal that prevents backward flow into the atria.

The structural integrity of this seal depends on the coordinated function of the valve leaflets, the chordae tendineae (fibrous tendons that tether the leaflets to the ventricular wall), the papillary muscles, and the mitral annulus (the fibrous ring supporting the valve). Dysfunction of any component can result in MVP.

What Happens in Mitral Valve Prolapse

In mitral valve prolapse, when the left ventricle contracts during systole, one or both mitral leaflets balloon backward (prolapse) into the left atrium rather than closing flush. This occurs because the leaflet tissue is abnormally redundant, thickened, or the chordae tendineae are too long or weak.

The consequence depends on the degree of leaflet coaptation failure:

• If the leaflets still manage to meet adequately: No regurgitation occurs, and the patient experiences no hemodynamic consequences. This is the situation in the majority of MVP patients.

• If the leaflets fail to close properly: Blood leaks backward from the left ventricle into the left atrium during systole, which is known as mitral regurgitation. The severity of this backward leak (graded as mild, moderate, or severe) determines the clinical significance and guides treatment decisions.

---

Causes

The exact cause of mitral valve prolapse is not fully understood. In most patients, MVP is a congenital condition (present from birth) and tends to run in families, suggesting a significant genetic component. It is inherited in an autosomal dominant pattern in many affected families, though with variable expressivity.

MVP is particularly prevalent in patients with inherited connective tissue disorders, which weaken the structural proteins of the valve leaflets and supporting apparatus:

• Marfan syndrome: The most strongly associated connective tissue disorder; characterized by abnormalities in fibrillin-1 affecting the aorta, eyes, and musculoskeletal system as well as the mitral valve
• Ehlers-Danlos syndrome
• Loeys-Dietz syndrome
• Osteogenesis imperfecta

Types of Valve Abnormalities

The structural abnormalities underlying MVP can include:

• Leaflet redundancy and thickening: The leaflets are excessively large, voluminous, or thickened (myxomatous degeneration, which is the accumulation of abnormal proteoglycans in the valve matrix)
• Elongated or ruptured chordae tendineae: The fibrous tendons supporting the leaflets become excessively long or, in advanced cases, rupture, causing sudden severe regurgitation
• Annular dilatation: Enlargement of the mitral annulus reduces leaflet coaptation
• Combined abnormalities: Multiple structural defects may coexist in the same patient

Risk Factors

MVP can affect people of all ages and both sexes. However:

• Severe complications are significantly more common in men over 50 years of age
• Women are more commonly diagnosed, but their disease is often milder

Conditions associated with increased risk of MVP include:

• Connective tissue disorders: Marfan syndrome, Ehlers-Danlos syndrome
• Scoliosis and other skeletal abnormalities (pectus excavatum, also known as sunken chest, is particularly associated with MVP)
• Certain forms of muscular dystrophy
• Graves’ disease (autoimmune hyperthyroidism)

---

Symptoms

The majority of patients with MVP are completely asymptomatic and discover the condition incidentally during a routine cardiac examination. In patients without significant regurgitation, no symptoms develop and no treatment is required.

When symptoms do occur, they may include:

• Palpitations: A sensation of the heart skipping beats, fluttering, pounding, or racing, often the most distressing symptom. Usually caused by benign arrhythmias (extrasystoles) but occasionally by more significant rhythm disturbances.
• Shortness of breath: Initially on exertion; may progress to dyspnea at rest with worsening regurgitation.
• Cough: Non-productive, related to elevated pulmonary venous pressure in significant regurgitation.
• Fatigue: Generalized, often out of proportion to physical exertion; may reflect reduced cardiac output.
• Dizziness or lightheadedness: Particularly with position changes or during arrhythmic episodes.
• Anxiety: MVP has been associated with dysautonomia (autonomic nervous system dysfunction), contributing to anxiety, palpitations, and chest discomfort.
• Migraine headache: MVP is more prevalent in migraine sufferers, possibly linked to platelet activation or autonomic dysfunction.
• Chest pain or discomfort: Typically atypical, not the classic exertional angina of coronary artery disease. It is often described as sharp, positional, or prolonged. Its mechanism in MVP is not fully understood.

Symptoms tend to be mild in most patients. They may, however, worsen over time, particularly as regurgitation progresses or if complications develop.

Important clinical note: Many of the symptoms attributed to MVP (particularly atypical chest pain, palpitations, fatigue, and anxiety) may overlap with anxiety disorders, panic disorder, and dysautonomia. A careful cardiac evaluation is always necessary to distinguish cardiac from non-cardiac causes.

---

Risks and Complications

Serious complications of MVP are relatively rare and are predominantly related to the presence and severity of mitral regurgitation. The risk of complications is substantially higher in patients with significant regurgitation and is particularly elevated in older men.

Arrhythmias

Cardiac arrhythmias, abnormalities in the rate or rhythm of the heartbeat, represent the most common complication of MVP. Most are benign (isolated premature atrial or ventricular contractions), but some can be serious:

• Atrial fibrillation (AF): The most clinically important arrhythmia in the context of MVP. During AF, the atrial walls quiver irregularly rather than contracting effectively, reducing blood flow to the ventricles and causing:

  • Irregular heartbeat, palpitations, fatigue, and dyspnea.
  • Risk of thrombus (blood clot) formation in the left atrium, where blood “stagnates” due to ineffective atrial contraction. If a clot detaches and travels to the brain, it causes a stroke, a potentially devastating complication.

• Ventricular arrhythmias: More rarely, MVP, particularly when associated with specific patterns of myocardial fibrosis detected on cardiac MRI, can cause ventricular tachycardia or, in rare cases, predispose to sudden cardiac death. This risk is higher in patients with severe regurgitation, significant leaflet thickening, or fibrotic changes in the posteromedial papillary muscle.

The chronic volume overload imposed by significant mitral regurgitation progressively dilates and stresses the left atrium and ventricle, creating the substrate for arrhythmia development over time.

Infective Endocarditis

Abnormal or structurally altered mitral leaflets can trap bacteria circulating in the bloodstream. These bacteria adhere to the damaged valve surface and proliferate, causing infective endocarditis (a serious infection of the heart valve and inner cardiac lining).

Symptoms of infective endocarditis include:

• Fever often high and persistent
• Chills and rigors
• Joint pain
• Headache
• Night sweats, fatigue, and weight loss
• New or changing cardiac murmur
• Embolic phenomena (stroke, splinter hemorrhages, Janeway lesions)

While endocarditis is fortunately uncommon, it can be life-threatening and is associated with significant morbidity. Among structural cardiac conditions, MVP, particularly when associated with regurgitation, is one of the lesions most commonly implicated in endocarditis.

Prevention is key: meticulous oral hygiene is the most important preventive measure for MVP patients. Dental caries and gum infections can introduce bacteria into the bloodstream and trigger endocarditis. Professional dental cleaning every 6 months is strongly advised.

Current international guidelines (AHA/ESC) no longer recommend routine antibiotic prophylaxis before dental procedures for all MVP patients. Prophylaxis is now reserved for a small high-risk subgroup: patients with a history of previous endocarditis, those with prosthetic heart valves, or those with specific congenital heart defects. Discuss your individual need for prophylaxis with your cardiologist and dentist.

---

Diagnosis

The modern diagnostic approach to MVP focuses not only on confirming the anatomical abnormality but also on quantifying the severity of regurgitation and stratifying the risk of future complications, guiding individualized management decisions.

Initial Clinical Assessment

MVP is often first suspected during a routine medical examination through cardiac auscultation. The characteristic finding is a midsystolic click, a brief, sharp, high-pitched sound produced by the sudden tensioning of the chordae tendineae when the prolapsing leaflets reach maximum displacement. This click is best heard at the cardiac apex or left sternal border.

If mitral regurgitation is also present, the click is followed by a systolic murmur, a whooshing sound that reflects the turbulent backward flow of blood through the incompetent valve. Both findings are dynamic; they shift in timing with changes in body position, which is a characteristic feature that helps distinguish MVP from other cardiac conditions.

An abnormal heart murmur detected during auscultation should always prompt referral for echocardiography.

Echocardiography: The Gold Standard

Transthoracic echocardiography (TTE) is the cornerstone diagnostic test for MVP. Using ultrasound imaging, it allows:

• Anatomical assessment: Visualization of the mitral leaflets, identifying prolapse, leaflet thickening, redundancy, annular dilatation, and chordal abnormalities. Modern 3D echocardiography provides millimetric spatial resolution, enabling precise identification of which specific segment(s) of the leaflet are involved. This information is critical for surgical planning.

• Functional assessment: Color Doppler echocardiography allows quantification of the regurgitant jet, which is the volume of blood flowing backward through the valve. Regurgitation is graded as mild, moderate, or severe based on standardized echocardiographic parameters (vena contracta width, effective regurgitant orifice area [EROA], regurgitant volume and fraction).

• Cardiac chamber assessment: Measurement of left ventricular and left atrial dimensions and function, which are key indicators of the hemodynamic impact of regurgitation and the timing of intervention.

Transesophageal echocardiography (TEE): In selected cases, particularly when image quality is suboptimal or for detailed pre-surgical planning, a thin ultrasound probe is introduced into the esophagus, which lies immediately posterior to the heart. TEE provides superior image quality by eliminating interference from the ribs and lungs, offering exquisite valve anatomy detail.

Advanced Imaging and Monitoring

• Cardiac Magnetic Resonance Imaging (CMR / Cardiac MRI): Increasingly used in complex or diagnostically uncertain cases. CMR is now considered the most accurate non-invasive method for measuring cardiac chamber volumes and regurgitant volume. It is also unique in its ability to identify myocardial fibrosis (small areas of scarring) within the ventricular wall using late gadolinium enhancement. Fibrosis in the papillary muscles or subvalvular apparatus is associated with a higher risk of ventricular arrhythmias and sudden cardiac death, informing risk stratification.

• 24-Hour Holter ECG monitoring: Essential for detecting silent arrhythmias and characterizing the nature of reported palpitations. Extended monitoring (2 weeks or longer) using implantable loop recorders may be considered in patients with unexplained syncope or suspected paroxysmal arrhythmias.

• Exercise stress testing: Evaluates the functional response of the heart and valve to physical exertion. It is particularly valuable in patients who report being “asymptomatic” but may have unconsciously reduced their activity level to avoid symptoms.

• Standard ECG and chest X-ray: Useful as complementary first-line investigations. ECG may show signs of left atrial enlargement, repolarization changes, or arrhythmias; chest X-ray may reveal cardiomegaly or pulmonary congestion in advanced disease.

---

Treatment

Treatment of mitral valve prolapse is highly individualized, based on the patient’s symptom burden, severity of regurgitation, cardiac chamber dimensions, left ventricular function, and overall risk profile. The primary therapeutic objectives are to preserve left ventricular function, prevent heart failure, and minimize the risk of serious arrhythmias.

Mild Cases and Surveillance

The vast majority of patients with isolated MVP and absent or mild regurgitation require no active treatment. The cornerstone of management is periodic surveillance with echocardiography:

• Mild MVP, no or trace regurgitation: Echocardiographic follow-up every 3–5 years is generally sufficient
• Mild-to-moderate regurgitation with normal cardiac dimensions: Annual or biennial echocardiographic review
• Severe regurgitation with preserved ventricular function: Closer monitoring (every 6–12 months) to identify the optimal timing for intervention before ventricular dysfunction develops

Patient reassurance is essential: the great majority of individuals with this diagnosis will live entirely normal lives without the need for any intervention.

Pharmacological Therapy

Medications cannot correct the anatomical defect of the valve, but they effectively manage symptoms and prevent complications:

• Beta-blockers (e.g., metoprolol, bisoprolol, atenolol): The first-choice treatment for patients experiencing symptomatic palpitations, atypical chest pain, or anxiety related to MVP. They reduce heart rate, blunt adrenergic surges, and decrease the mechanical force of ventricular contraction on the prolapsing leaflets, often significantly reducing symptom burden.

• Oral anticoagulants: Mandatory when atrial fibrillation develops, to prevent thromboembolic stroke. Direct oral anticoagulants (DOACs), such as rivaroxaban, apixaban, dabigatran, and edoxaban, are now preferred over traditional warfarin due to their superior ease of use, predictable pharmacokinetics, and favorable safety profile.

• Diuretics: Used in patients with significant regurgitation and symptoms of pulmonary congestion (fluid overload), to reduce preload and alleviate shortness of breath.

• Vasodilators and antihypertensives (ACE inhibitors, ARBs): Help reduce the hemodynamic burden on the left ventricle in patients with significant regurgitation, particularly when hypertension coexists.

Surgical Repair: The Preferred Approach

Surgery becomes necessary when mitral regurgitation is severe, or when signs of early cardiac dysfunction develop.

Standard surgical indications (per current ESC/AHA guidelines) include:

• Severe symptomatic mitral regurgitation (any symptom attributable to the valve lesion)
• Severe asymptomatic regurgitation with:
  • Left ventricular ejection fraction ≤60% (early systolic dysfunction)
  • Left ventricular end-systolic diameter ≥40–45 mm (progressive dilatation)
  • New-onset atrial fibrillation attributable to the mitral lesion
  • Significant pulmonary hypertension on exercise

Valve Repair vs. Valve Replacement

The overwhelming consensus in contemporary cardiology is that mitral valve repair is vastly superior to replacement whenever technically feasible:

Repair techniques include annuloplasty ring implantation (to restore normal annular dimensions), leaflet resection or plication (removing the prolapsing segment), chordal replacement with artificial PTFE sutures (neo-chordae), and other reconstructive maneuvers, all tailored to the specific anatomical defect.

Minimally invasive approaches: Many experienced centers now perform mitral valve repair through small intercostal incisions (mini-thoracotomy) or with robotic-assisted surgery, significantly reducing surgical trauma, blood loss, hospital stay, and recovery time compared to conventional median sternotomy (open-heart surgery).

Valve replacement is reserved for cases where repair is not technically possible:

• Mechanical prostheses: Extremely durable (potentially lifelong) but require permanent anticoagulation with its associated risks
• Biological (bioprosthetic) prostheses: Do not require long-term anticoagulation, but structurally deteriorate over 10–15 years, typically necessitating re-intervention

Percutaneous (Catheter-Based) Treatments

For patients considered too high-risk for conventional surgery (due to advanced age, frailty, or significant comorbidities), catheter-based procedures offer a less invasive alternative:

• MitraClip (transcatheter edge-to-edge repair, TEER): A small metal clip is delivered through the femoral vein, advanced across the interatrial septum, and used to grasp and approximate the two mitral leaflets, reducing regurgitation by creating a double-orifice valve. The procedure is performed without opening the chest, under general anesthesia, and typically results in a significantly shorter recovery time than surgery. While less durable than surgical repair in suitable anatomical candidates, it provides meaningful symptom relief and quality-of-life improvement in high-surgical-risk patients.

• Transcatheter mitral valve replacement (TMVR): Still largely under clinical investigation for primary MVP regurgitation, but representing a rapidly evolving field.

Lifestyle and Prevention

An active, health-conscious lifestyle is strongly encouraged:

• Physical activity: Regular moderate exercise is beneficial for cardiovascular health and is generally safe and recommended for the vast majority of MVP patients. Only in specific high-risk scenarios, such as severe regurgitation, significant ventricular dysfunction, or documented complex ventricular arrhythmias, may competitive athletics or very intense training require restriction. This should be individually determined with a sports cardiologist.

• Meticulous oral hygiene: The most effective behavioral intervention to prevent infective endocarditis. Professional dental cleaning every 6 months, combined with daily brushing and flossing, significantly reduces the bacterial burden and the risk of bacteremia that could seed the valve. Prompt treatment of any dental or gum infection is essential.

• Blood pressure control: Maintaining blood pressure within the normal range (ideally <130/80 mmHg) is crucial. Hypertension increases the regurgitant volume and accelerates left ventricular remodeling, potentially hastening the need for surgery.

• Avoiding stimulants: In patients with palpitations, it is advisable to reduce or eliminate caffeine, tobacco, and excessive alcohol, as these can all precipitate arrhythmias.

---

Frequently Asked Questions

I received an echocardiography report showing mild mitral and tricuspid regurgitation. Will I need surgery?

Mild mitral and tricuspid regurgitation is very common. Often, it is simply a normal variant. In the vast majority of cases, it is entirely benign and does not require surgical intervention. Management is typically limited to periodic echocardiographic surveillance to ensure that regurgitation does not progress over time. Surgery is only considered when regurgitation becomes severe or begins to affect cardiac function. Always discuss your specific report with your cardiologist for a personalized assessment.

My doctor diagnosed me with mitral valve prolapse. Is this condition congenital or can it develop over time?

In most cases, MVP is indeed congenital, present from birth, though it may only be detected in adulthood. It tends to run in families, reflecting a genetic predisposition. In some patients, the valve abnormality is present from birth but becomes more apparent over decades, as the degenerative changes (myxomatous degeneration) progress. Isolated acquired MVP without any underlying structural predisposition is uncommon.

I have symptoms like fatigue, palpitations, and chest pain related to my MVP. What should I do?

Consult your cardiologist promptly, particularly if these symptoms are new or worsening. Your doctor will assess whether the symptoms are directly related to valve dysfunction or regurgitation, or whether they reflect dysautonomia, anxiety, or benign arrhythmias. All of these conditions are manageable. Never attribute new or progressive cardiac symptoms to MVP without proper evaluation, as some may require specific treatment.

Do I need to take antibiotics before dental procedures because of my MVP?

Not routinely. Current international guidelines (ESC and AHA) have significantly narrowed the indications for antibiotic prophylaxis before dental procedures. Prophylaxis is now recommended only for high-risk patients: those with a history of previous infective endocarditis, those with prosthetic heart valves or prosthetic repair material, or those with certain complex congenital heart defects. Most patients with uncomplicated MVP, even with mild regurgitation, do not require routine antibiotic prophylaxis. However, meticulous oral hygiene is strongly recommended for all MVP patients. Discuss your individual situation with both your cardiologist and dentist before any procedure.

Can patients with MVP exercise normally?

Yes, for the vast majority of MVP patients, regular physical activity is not only safe but actively encouraged. The exception is competitive high-intensity athletics in patients with severe regurgitation, significant ventricular dysfunction, or specific high-risk arrhythmia patterns. In these cases, activity restrictions should be determined individually with a sports cardiologist.

---

Sources and Bibliography

• NIH National Heart, Lung, and Blood Institute: Heart Valve Diseases
• Vahanian A et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. PubMed
• Otto CM et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197. PubMed
• Devereux RB et al. Mitral valve prolapse. N Engl J Med. 1999;341(1):1-7. PubMed
• Freed LA et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1-7. PubMed
• Suri RM et al. Robotic mitral valve repair for all prolapse subsets using techniques identical to open valvuloplasty: establishing the benchmark against which percutaneous interventions should be judged. J Thorac Cardiovasc Surg. 2011;142(5):970-979.
• American Heart Association: Mitral Valve Prolapse
• Mayo Clinic: Mitral Valve Prolapse
• NHS: Mitral Valve Problems